Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™

CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the closing of its licensing agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, it …

Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™ Read More »